1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock we elected to purchase from Sanofi pursuant to the terms of the Letter Agreement relating to Sanofi's funding obligation in connection with (i) Libtayo development costs incurred under the IO License and Collaboration Agreement and (ii) certain activities relating to dupilumab and REGN3500 incurred under the LCA, during the first quarter of 2020 .
+Added: The table below reflects shares of Common Stock purchased directly from Sanofi, Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted equity awards granted under one of our long-term incentive plans, and Common Stock we elected to purchase from Sanofi pursuant to the terms of the Letter Agreement relating to Sanofi's funding obligation in connection with (i) Libtayo development costs incurred under the IO License and Collaboration Agreement and (ii) certain activities relating to dupilumab and REGN3500 incurred under the LCA, during the three months ended June 30, 2020.
Refer to Part I, Item 2.
−Removed: "Liquidity and Capital Resources - Share Repurchase Program " and "Liquidity and Capital Resources - Sanofi Funding of Certain Development Costs " for further information.
−Removed: Total Number of Shares Purchased
−Removed: Average Price Paid per Share
−Removed: Total Number of Shares Purchased as Part of a Publicly Announced Program
−Removed: Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
+Added: "Liquidity and Capital Resources" for further information.
+Added: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of a Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (1)
4/1/2020–4/30/2020 1,122 $ 510.37 — 473,117,435
1 unchanged sentence
6/1/2020–6/30/2020 120,234
−Removed: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is related to Common Stock we elected to purchase from Sanofi (as described above).
−Removed: Exhibit Number
−Removed: Preferability letter from PricewaterhouseCoopers LLP regarding change in accounting principle.
+Added: Total 9,928,161
+Added: (1) Relates to our share repurchase program.
+Added: Refer to Part I, Item 2.
+Added: "Liquidity and Capital Resources - Share Repurchase Program" for further details.
+Added: Exhibit Number Description
+Added: Second Amended and Restated Regeneron Pharmaceuticals, Inc.
+Added: 2014 Long-Term Incentive Plan.
+Added: (Incorporated by reference from the Registration Statement on Form S-8 for the Registrant, filed June 16, 2020.)
+Added: 10.2 Credit Agreement, dated as of May 25, 2020, by and among the Registrant, as borrower;
+Added: Goldman Sachs Bank USA, as administrative agent, sole bookrunner, sole lead arranger, and a lender;
+Added: and the other lenders party thereto from time to time.
+Added: (Incorporated by reference from the Form 8-K for the Registrant, filed May 29, 2020.)
+Added: 10.2.1 Amendment No.
+Added: 1 to Credit Agreement, dated as of June 11, 2020, by and between the Registrant, as borrower, and Goldman Sachs Bank USA, as administrative agent .
+Added: Third Amendment to Amended and Restated License and Collaboration Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi.
+Added: Praluent Cross License & Commercialization Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant and Sanofi Biotechnology SAS.
+Added: 10.5 Stock Repurchase Agreement, dated as of May 25, 2020, by and between the Registrant and Sanofi.
+Added: (Incorporated by reference from the Form 8-K for the Registrant, filed May 29, 2020.)
+Added: 10.6 Amendment to the Amended and Restated Investor Agreement, dated as of May 25, 2020, by and among the Registrant, Sanofi, Sanofi-Aventis US LLC, and Aventisub LLC.
+Added: (Incorporated by reference from the Form 8-K for the Registrant, filed May 29, 2020.)
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
3 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the Registrant's Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019;
−Removed: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2020 and 2019;
−Removed: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2020 and 2019;
−Removed: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019;
+Added: (i) the Registrant's Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019;
+Added: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2020 and 2019;
+Added: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2020 and 2019;
+Added: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and 2019;
and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
+Added: + Indicates a management contract or compensatory plan or arrangement.
+Added: * Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
REGENERON PHARMACEUTICALS, INC.
+Added: August 5, 2020 By:
/s/ Robert E.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.